HypotrichosisPhase 4NCT07776028
Efficacy and Safety of Dallixa® Eyelash Serum in Idiopathic Eyelash Hypotrichosis
A Phase 4 study testing dermo cosmetic product in people with Hypotrichosis, run by Quantum Aesthetics Cosmetics at 1 site in Turkey (Türkiye).
Trial summary
Efficacy and Safety of Dallixa® Eyelash Serum in Idiopathic Eyelash Hypotrichosis Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Hypotrichosis
- What is being tested?
- dermo cosmetic product
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 37 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 28 Aug 2025to 17 Feb 2026
- Phase
- Phase 4
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Individuals of any sex and at least 18 years of age
- Subjects who have inadequate eyelashes due to natural causes (Idiopathic eyelash hypotrichosis)
- Eyelash prominence assessment of minimal or moderate
- A score of 1 or 2 on the clinician-graded Global Eyelash Assessment (GEA)
- Willing to complete all required study visits, procedures, and evaluations including photography.
Who cannot join
- Subjects with unequal right and left eyelashes or no visible eyelashes
- Damage to eyelid area (scarring) that may prevent growth of eyelashes
- Any uncontrolled systemic disease
- Any disease, infection, or abnormality of the eye or in the area around the eye and the current use of ophthalmic medication (glaucoma, uveitis, eye infections, chronic blepharitis or severe dry eye)
- Any ocular (eye or eyelid) surgery within 3 months or anticipated need for ocular surgery during the study (including laser, refractive, intraocular filtering surgery, blepharoplasty)
- Any permanent eyeliner or implants of any kind, or anticipated use of false eyelashes
Show all 14Show fewer
- Any semi-permanent eyelash tint, dye, curl, or eyelash extension application within 3 months
- Use of any over-the-counter or prescription eyelash growth product within 3 months
- Use of treatments which may affect hair growth (eg, minoxidil, chemotherapy) within 6 months
- Unable or unwilling to keep contact lenses out during product application and for 30 minutes after application
- Severe hyperpigmentation around the eye
- Allergy to any component of the investigational product
- Females who are pregnant, nursing, or planning a pregnancy during the study, or who are of childbearing potential and not using a reliable method of contraception
- Current enrollment in an investigational product or device or participation in such a study within 30 days
Trial locations and contacts
1 site in 1 country.
Turkey (Türkiye)1 site
Akdeniz Üniversitesi Hastanesi
Antalya, Antalya
About this study
Official title: Evaluation of the Efficacy and Safety of Dallixa® Eyelash Serum (Produced by Quantum Aesthetics Cosmetics, Turkey) in Subjects With Idiopathic Eyelash Hypotrichosis
Efficacy and Safety of Dallixa® Eyelash Serum in Idiopathic Eyelash Hypotrichosis
- Conditions
- Hypotrichosis
- Being tested
- dermo cosmetic product
- Medical subject headings
- Hypotrichosis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
dermo cosmetic productDrug
dermo cosmetic products like herbal or vitamin ingredients
| Study group | Role | What they receive |
|---|---|---|
| Dallixa® Eyelash Serum | Experimental | Not described Receives: Drug: dermo cosmetic product |
What is being measured
The primary outcome is the main question the study is designed to answer.
The proportion of subjects with ≥ 1-grade increase in the GEA at month 4
Measured: 4 month
Secondary outcomes (6)
The proportion of subjects with ≥ 1-grade increase in the GEA at month 2
Measured: 2month
The proportion of subjects with ≥ 2-grade increase in the GEA at month 2 and 4
Measured: at2 and4 month
Change from baseline in upper eyelash length (mm) at month 2 and 4 (Based on DIA)
Measured: at 2 and 4 month
Change from baseline in average progressive upper eyelash thickness (mm2) at month 2 and 4 (Based on DIA)
Measured: at 2 and 4 month
Percentage of Participants Satisfied or Very Satisfied in the Patient's Assessment of Overall Eyelash Satisfaction as Measured by the Eyelash Satisfaction Questionnaire (ESQ-9) at month 2 and 4
Measured: at 2 and4 month
Adverse events reported from the baseline and during the study period (from the baseline up to week 16)
Measured: from the baseline up to week 16
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Aug 2026
- Study start28 Aug 2025
- Primary completion17 Feb 2026
- Study completion17 Feb 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HypotrichosisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- A retrospective, single arm, and interventional Clinical Trial
- Masking
- None (open label)
- Enrolment
- 37 participants (actual)
Sponsor and investigators
- Lead sponsor
- Quantum Aesthetics Cosmetics
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07776028
- Sponsor's protocol ID
- DallKirpik.Qua.AA.IV.2025
- Status last verified
- Nov 2026
- First submitted
- 17 Aug 2026
- Last updated
- 6 Nov 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: no plan to share the individual participant data yet
Study at a glance
From the registry record, last updated by the sponsor on 6 Nov 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of the Efficacy and Safety of Dallixa® Eyelash Serum (Produced by Quantum Aesthetics Cosmetics, Turkey) in Subjects With Idiopathic Eyelash Hypotrichosis
- ClinicalTrials.gov ID
- NCT07776028
- Acronym / sponsor ID
- DallKirpik.Qua.AA.IV.2025
- Conditions
- Hypotrichosis
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 37 participants (actual)
- Lead sponsor
- Quantum Aesthetics CosmeticsIndustry (pharma, biotech, devices)
- Study start
- 28 Aug 2025 (actual)
- Primary completion
- 17 Feb 2026 (actual)
- Study completion
- 17 Feb 2026 (actual)
- First posted
- 20 Aug 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Efficacy and Safety of Dallixa® Eyelash Serum in Idiopathic Eyelash Hypotrichosis
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- A retrospective, single arm, and interventional Clinical Trial
| Arm | Type | Receives |
|---|---|---|
| Dallixa® Eyelash Serum | Experimental | Drug: dermo cosmetic product |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Individuals of any sex and at least 18 years of age
- Subjects who have inadequate eyelashes due to natural causes (Idiopathic eyelash hypotrichosis)
- Eyelash prominence assessment of minimal or moderate
- Willing to complete all required study visits, procedures, and evaluations including photography.
Key exclusion criteria (14 listed)
- Subjects with unequal right and left eyelashes or no visible eyelashes
- Damage to eyelid area (scarring) that may prevent growth of eyelashes
- Any uncontrolled systemic disease
- Any disease, infection, or abnormality of the eye or in the area around the eye and the current use of ophthalmic medication (glaucoma, uveitis, eye infections, chronic blepharitis or severe dry eye)
- Any ocular (eye or eyelid) surgery within 3 months or anticipated need for ocular surgery during the study (including laser, refractive, intraocular filtering surgery, blepharoplasty)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| dermo cosmetic productdermo cosmetic products like herbal or vitamin ingredients | Drug | Dallixa® Eyelash Serum |
Primary outcome
The proportion of subjects with ≥ 1-grade increase in the GEA at month 4
Time frame: 4 month
6 secondary outcomes
The proportion of subjects with ≥ 1-grade increase in the GEA at month 2
Time frame: 2month
The proportion of subjects with ≥ 2-grade increase in the GEA at month 2 and 4
Time frame: at2 and4 month
Change from baseline in upper eyelash length (mm) at month 2 and 4 (Based on DIA)
Time frame: at 2 and 4 month
Change from baseline in average progressive upper eyelash thickness (mm2) at month 2 and 4 (Based on DIA)
Time frame: at 2 and 4 month
Percentage of Participants Satisfied or Very Satisfied in the Patient's Assessment of Overall Eyelash Satisfaction as Measured by the Eyelash Satisfaction Questionnaire (ESQ-9) at month 2 and 4
Time frame: at 2 and4 month
Adverse events reported from the baseline and during the study period (from the baseline up to week 16)
Time frame: from the baseline up to week 16
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Nov 2026.
- Individual participant dataSharing planned: No. no plan to share the individual participant data yet
Related trials for Hypotrichosis
Active, not recruitingPhase 3
A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata
Severe Alopecia Areata
RecruitingPhase 2
Evaluate the Efficacy and Safety of Ruxolitinib on Hair Regrowth in Patients With Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED)-Associated Alopecia Areata
Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (Apeced), Alopecia Areata
Active, not recruitingObservational study
Litfulo Capsules Special Investigation
Alopecia Areata
Active, not recruitingObservational study
Real-World Effectiveness of Ritlecitinib in Alopecia Areata Patients in the US: A Retrospective Analysis Using EHR and Claims Data
Alopecia Areata
Active, not recruitingObservational study
Characterization And Clinical Outcomes of AA Patients Treated With Ritlecitinib
Alopecia Areata
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing dermo cosmetic product in people with Hypotrichosis, run by Quantum Aesthetics Cosmetics at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 14 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 6 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The proportion of subjects with ≥ 1-grade increase in the GEA at month 4 (time frame: 4 month). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Nov 2026.